S
Stephan A. Grupp
Researcher at Children's Hospital of Philadelphia
Publications - 396
Citations - 44427
Stephan A. Grupp is an academic researcher from Children's Hospital of Philadelphia. The author has contributed to research in topics: Chimeric antigen receptor & Transplantation. The author has an hindex of 77, co-authored 366 publications receiving 34450 citations. Previous affiliations of Stephan A. Grupp include University of Pennsylvania & St. Jude Children's Research Hospital.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia
Hidefumi Hiramatsu,Souichi Adachi,Katsutsugu Umeda,Itaru Kato,Lamis K. Eldjerou,Andrea Chassot Agostinho,Kazuto Natsume,Kota Tokushige,Yoko Watanabe,Stephan A. Grupp +9 more
TL;DR: Tisagenlecleucel produced high remission rates and durable responses offering a new treatment option for Japanese pediatric and young adults with r/r B-ALL.
Journal ArticleDOI
Phase-1 study of siplizumab in the treatment of pediatric patients with at least grade II newly diagnosed acute graft-versus-host disease.
TL;DR: A Phase‐1 study of siplizumab in the treatment of pediatric patients with at least grade II newly diagnosed acute graft‐versus‐host disease and its application in children with severe central giant cell granuloma.
Journal ArticleDOI
Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF): Results of a Treatment IND Expanded Access Protocol
Paul G. Richardson,Angela R. Smith,Sally Arai,Stephan A. Grupp,Nancy A. Kernan,Roberta H. Adams,Paul L. Martin,Sunil Abhyankar,Alfred P. Gillio,Michael Grimley,Leslie Lehmann,Paul R. Haut,Amanda Termuhlen,Joseph H. Antin,Thomas R. Spitzer,David Avigan,Joseph M. Massaro,Alison L. Hannah,Massimo Iacobelli,Robert J. Soiffer +19 more
TL;DR: DF in the treatment of severe VOD/MOF post-SCT demonstrated a complete response (CR) in 36–46% of patients, and key exclusion criteria included clinically significant bleeding or need for >1 pressor to maintain BP.
Journal ArticleDOI
Humanized chimeric antigen receptor (CAR)-modified T cells targeting CD19 induce remissions in children and young adults with relapsed/refractory lymphoblastic leukemia/lymphoma
George E Hucks,David M. Barrett,Susan R. Rheingold,Richard Aplenc,David T. Teachey,Colleen Callahan,Diane Baniewicz,Claire White,Mala K. Talekar,Pamela A. Shaw,Jennifer Brogdon,Regina M. Young,John Scholler,Katherine T. Marcucci,Anne Chew,Bruce L. Levine,Noelle V. Frey,David L. Porter,Simon F. Lacey,J. Joseph Melenhorst,Carl H. June,Stephan A. Grupp,Shannon L. Maude +22 more
Journal ArticleDOI
Immunotherapy for Pediatric Cancer
TL;DR: This review explores how 3 components of the immune system--T cells, natural killer (NK) cells, and antibodies--can be used for therapy of pediatric malignancies.